During the last session, Calidi Biotherapeutics Inc (AMEX:CLDI)’s traded shares were 3.36 million, with the beta value of the company hitting 1.09. At the end of the trading day, the stock’s price was $1.50, reflecting an intraday gain of 22.95% or $0.28. The 52-week high for the CLDI share is $16.80, that puts it down -1020.0 from that peak though still a striking 61.33% gain since the share price plummeted to a 52-week low of $0.58. The company’s market capitalization is $38.88M, and the average intraday trading volume over the past 10 days was 4.31 million shares, and the average trade volume was 2.24 million shares over the past three months.
Calidi Biotherapeutics Inc (AMEX:CLDI) trade information
Calidi Biotherapeutics Inc (CLDI) registered a 22.95% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 22.95% in intraday trading to $1.50, hitting a weekly high. The stock’s 5-day price performance is 10.29%, and it has moved by 63.26% in 30 days. Based on these gigs, the overall price performance for the year is -74.31%. The short interest in Calidi Biotherapeutics Inc (AMEX:CLDI) is 0.59 million shares and it means that shorts have 0.88 day(s) to cover.
The consensus price target of analysts on Wall Street is $5.5, which implies an increase of 72.73% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2 and $9 respectively. As a result, CLDI is trading at a discount of -500.0% off the target high and -33.33% off the low.
Calidi Biotherapeutics Inc (CLDI) estimates and forecasts
Statistics show that Calidi Biotherapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Calidi Biotherapeutics Inc (CLDI) shares have gone down -14.29% during the last six months, with a year-to-date growth rate more than the industry average at 74.10% against 15.80.
While earnings are projected to return 78.64% in 2025, the next five years will return 69.01% per annum.
CLDI Dividends
Calidi Biotherapeutics Inc is due to release its next quarterly earnings in March. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Calidi Biotherapeutics Inc (AMEX:CLDI)’s Major holders
Calidi Biotherapeutics Inc insiders own 18.16% of total outstanding shares while institutional holders control 2.71%, with the float percentage being 3.31%. RED WAVE INVESTMENTS LLC is the largest shareholder of the company, while 34.0 institutions own stock in it. As of 2024-06-30, the company held over 0.62 million shares (or 1.1723% of all shares), a total value of $0.12 million in shares.
The next largest institutional holding, with 0.56 million shares, is of CPR INVESTMENTS INC.’s that is approximately 1.0511% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $0.11 million.
Also, the Mutual Funds coming in first place with the largest holdings of Calidi Biotherapeutics Inc (CLDI) shares are Fidelity Extended Market Index Fund and Bridgeway Funds Inc-Ultra Small Company Market Fund . Data provided on Nov 30, 2024 indicates that Fidelity Extended Market Index Fund owns about 30.96 shares. This amounts to just over 0.11 percent of the company’s overall shares, with a $46443.0 market value. The same data shows that the other fund manager holds slightly less at 10.0, or about 0.04% of the stock, which is worth about $15000.0.
